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Abstract: Staphylococcus aureus is an important pathogen and biofilm former. Biofilms cause
problems in clinics and food production and are highly recalcitrant to antibiotics and sanitizers.
Bacteriophage endolysins kill bacteria by degrading their cell wall and are therefore deemed
promising antimicrobials and anti-biofilm agents. Depolymerases targeting polysaccharides in the
extracellular matrix have been suggested as parts of a multi-enzyme approach to eradicate biofilms.
The efficacy of endolysins and depolymerases against S. aureus biofilms in static models has been
demonstrated. However, there is a lack of studies evaluating their activity against biofilms grown
under more realistic conditions. Here, we investigated the efficacy of the endolysin LysK and the
poly-N-acetylglucosamine depolymerase DA7 against staphylococcal biofilms in static and dynamic
(flow cell-based) models. LysK showed activity against multiple S. aureus strains, and both LysK and
DA7 removed static and dynamic biofilms from polystyrene and glass surfaces at low micromolar
and nanomolar concentrations, respectively. When combined, the enzymes acted synergistically,
as demonstrated by crystal violet staining of static biofilms, significantly reducing viable cell counts
compared to individual enzyme treatment in the dynamic model, and confocal laser scanning
microscopy. Overall, our results suggest that LysK and DA7 are potent anti-biofilm agents, alone and
in combination.
Keywords: endolysin; depolymerase; biofilm; S. aureus; synergy; antimicrobial; dynamic model;
flow cell
1. Introduction
Staphylococcus aureus is an opportunistic bacterial pathogen which can cause a broad variety
of infectious diseases in both humans and animals. The long list of medical conditions caused
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by these Gram-positive bacteria includes abscesses of skin, muscles and various organs, infective
endocarditis, osteomyelitis, pneumonia, and toxic shock syndrome [1,2]. S. aureus can also exist in
polymicrobial biofilms of the oral cavity [3] and has frequently been implicated in oral infections,
such as peri-implantitis [4,5]. In addition, S. aureus is frequently responsible for food poisoning
via production of heat-stable enterotoxins [6]. Besides their important role as human pathogens,
staphylococci (and S. aureus in particular) are a major cause of bovine mastitis, an infection of the
mammary gland in cows. This leads to severe losses in milk production and quality and increased
costs due to veterinary treatment and culling of animals, making it the most costly disease for the dairy
industry [7]. In both human and veterinary clinics, the increasing prevalence of antibiotic-resistant
strains such as methicillin-resistant S. aureus (MRSA) as well as the ability of staphylococci to form
biofilms result in prolonged therapies and increased treatment costs [8,9].
Biofilms are sessile communities of bacteria embedded in a self-produced extracellular matrix that
can grow attached to biotic and abiotic surfaces and as free-floating pellicle structures. The extracellular
biofilm matrix consists of multiple components, including extracellular DNA, proteins, environmental
components and exopolysaccharides, which provide structure and resilience and often constitute the
major part of the matrix [10,11]. One exopolysaccharide frequently found in staphylococcal biofilms
is poly-N-acetylglucosamine (PNAG), also referred to as polysaccharide intercellular adhesin (PIA),
which is produced by enzymes encoded within the icaADBC operon [9]. The ability to form biofilms
represents an important virulence factor for many pathogenic bacteria, including staphylococci, and is
associated with an increased tolerance to antimicrobial agents and host defenses [12]. In addition,
in the food industry, biofilms on food processing surfaces cause major problems. Due to their high
levels of recalcitrance towards sanitizers and cleaning processes, they constitute permanent sources
of contamination [13]. In S. aureus-induced bovine mastitis, the formation of biofilms is believed to
contribute to bacterial persistence in the udder, the recurrence of intramammary infections, and the
difficulty to treat these infections [14].
Endolysins are bacteriophage-encoded peptidoglycan hydrolases with the function to lyse the
bacterial host cell by degrading its cell wall at the end of the lytic multiplication cycle of the phage.
In their natural context, endolysins gain access to their peptidoglycan substrate from within the
bacterial cell by help of cytoplasmic membrane-perforating holin proteins [15]. However, in the absence
of an outer membrane in Gram-positive bacteria, these enzymes can also access the peptidoglycan
and destroy the bacterial target cell from the outside, which renders them promising antibacterial
agents [16–18]. Their major advantages as antimicrobials include their rapid killing activity against
antibiotic-sensitive and -resistant strains, their specificity for their target bacteria, and their low chance
of resistance development. Numerous in vitro studies and animal models of bacterial infection have
demonstrated their efficacy as antimicrobial agents against multiple pathogens [19,20]. A recent study
compared the efficacies of nine unique peptidoglycan hydrolases including eight phage endolysins and
one bacteriocin against S. aureus, using multiple in vitro activity assays, a mouse model of systemic
MRSA infection, and a static biofilm reduction assay [21]. The most potent endolysin within this set
of enzymes, LysK [22], demonstrated high staphylolytic activity against all tested strains (including
MRSA strains and other clinical isolates), protected 100% of MRSA-infected mice from death, and was
the most effective endolysin at degrading S. aureus biofilms in the 96-well plate-based model [21].
Similar static biofilm models have also been employed to investigate the ability of other
endolysins [21,23–25] as well as various enzymes attacking the extracellular matrix to degrade
staphylococcal biofilms. The latter include DNase I, which can degrade extracellular DNA [26],
the Aggregatibacter actinomycetemcomitans-derived PNAG depolymerase dispersin B [27,28], and the
phage-derived exopolysaccharide depolymerase Dpo7 [29]. The combined application of such enzymes
that simultaneously target multiple components of a biofilm, thereby potentially capitalizing on
synergistic effects, has been suggested as a promising approach to prevent biofilm formation and to
eradicate mature biofilms [10]. While the static biofilm models used in the aforementioned studies may
provide first insights into the anti-biofilm activities of such agents, they insufficiently mimic natural
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conditions encountered in the human body or the food industry, where growing biofilms are often
exposed to shear forces under the continuous flow of liquids. Therefore, including more sophisticated
dynamic models such as flow-cell systems is desirable in studies evaluating the efficacy of anti-biofilm
agents [23,30,31].
Here, we further investigate the activity of the endolysin LysK against S. aureus biofilms,
employing both conventional static and flow-cell-based dynamic models. Moreover, we evaluate the
anti-biofilm efficacy of enzymes targeting the extracellular matrix, including a PNAG depolymerase
with homology to dispersin B, alone and in combination with LysK.
2. Materials and Methods
2.1. Bacterial Strains, Plasmids, and Culture Conditions
Escherichia coli strains XL1-Blue MRF’ and BL21-Gold(DE3) (Agilent Technologies, Santa Clara,
CA, USA) were used for cloning of A. actinomycetemcomitans-derived genes encoding different
depolymerase enzymes and expression of recombinant proteins. BL21-Gold(DE3) harboring a plasmid
construct coding for the S. aureus phage endolysin LysK in a pET-21a backbone (EMD Biosciences,
San Diego, CA, USA) served as expression strain for recombinant production of a C-terminally
6× His-tagged version of LysK [21]. E. coli strains were cultured at 37 ◦C in Luria-Bertani (LB)
medium supplemented with ampicillin (100 µg/mL; for BL21-Gold(DE3)) or ampicillin and tetracycline
(30 µg/mL; for XL1-Blue MRF’) for plasmid selection. S. aureus and A. actinomycetemcomitans strains
used in this work are listed in Table 1. S. aureus was routinely cultured aerobically in tryptic soy broth
(TSB; Biolife, Milan, Italy) at 37 ◦C, and A. actinomycetemcomitans was grown on DifcoTM Columbia
Blood Agar plates (BD, Allschwil, Switzerland) at 37 ◦C in the presence of 10% CO2.
Table 1. Bacterial strains used in this work.
Strain Characteristics Source, Reference
E. coli XL1-Blue MRF’ Cloning and expression strain 1
E. coli BL21-Gold(DE3) Cloning and expression strain 1
S. aureus SA113 (ATCC 35556) Strong biofilm former 2, [32]
S. aureus RN6911 agr-deficient mutant strain 3, [33]
S. aureus SA001 Bovine mastitis isolate 4, [34]
S. aureus Mastidis Bovine mastitis isolate 5
S. aureus 305 (Newbould) (ATCC 29740) Bovine mastitis isolate 6, [35]
S. aureus R174 Food isolate 5
S. aureus R177 Food isolate 5
S. aureus R191 Food isolate 5
S. aureus R192 Food isolate 5
S. aureus 319 Food isolate 5
S. aureus 350 Food isolate 5
S. aureus 2971 Food isolate 5
S. aureus 95 Food isolate 5
A. actinomycetemcomitans OMZ 542 Source of depolymerase 7
A. actinomycetemcomitans OMZ 247 Source of depolymerase 7
A. actinomycetemcomitans OMZ 295 Source of depolymerase 7
A. actinomycetemcomitans OMZ 296 Source of depolymerase 7
A. actinomycetemcomitans OMZ 534 Source of depolymerase 7
1 Agilent Technologies, Santa Clara, CA, USA; 2 Andreas Peschel, University of Tübingen, Tübingen, Germany;
3 Brigitte Berger-Bächi, University of Zurich, Zurich, Switzerland; 4 Yasunori Tanji, Tokyo Institute of Technology,
Yokohama, Japan; 5 Roger Stephan, University of Zurich, Zurich, Switzerland; 6 David M. Donovan, ARS, USDA,
Beltsville, MD, USA; 7 Georgios Belibasakis, Karolinska Institutet, Stockholm, Sweden (formerly at University of
Zurich, Zurich, Switzerland).
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2.2. DNA Techniques and Cloning Procedures
Standard molecular biology techniques [36] were used for cloning of recombinant
A. actinomycetemcomitans-derived depolymerase constructs. Colony material from 5 different
A. actinomycetemcomitans strains (Table 1) served as templates for PCR amplification of
respective genes using Phusion® High-Fidelity DNA Polymerase (New England Biolabs, Allschwil,
Switzerland). Primers were designed based on the nucleotide sequence of the previously described
A. actinomycetemcomitans-derived DspB depolymerase [27]. Primer pair DA_BamHI_F
(TGCAGGATCCAATTGTTGCGTAAAAGGC) and DA_SalI_R (ACTTGTCGACTTACTCATCCCC
ATTCGTC) was used for generation of N-terminally 6× His-tagged constructs, and primer pair
DA_NdeI_F (AGTCTGTTCACATATGAATTGTTGCGTAAAAGGC) and DA_XhoI_R (CTGATACT
CGAGCTCATCCCCATTCGTC) for generation of C-terminally 6× His-tagged proteins. Resulting
fragments were inserted into BamHI and SalI or NdeI and XhoI restriction sites of the plasmids pQE-30
(Qiagen, Hilden, Germany) or pET-21a (EMD Biosciences, San Diego, CA, USA), encoding N- or
C-terminal His-tags, respectively. The plasmid constructs were introduced into E. coli XL1-Blue MRF’
(for pQE-30-based constructs) or E. coli BL21-Gold(DE3) (for pET-21a-based constructs). All sequences
were verified by nucleotide sequencing (GATC, Konstanz, Germany).
2.3. Protein Expression and Purification
Expression of 6× His-tagged proteins in E. coli and purification via immobilized metal ion
affinity chromatography was performed essentially as previously described [37]. In brief, bacterial
cultures were grown in LB medium optimized for protein expression (LB-PE) [38] supplemented
with antibiotics for plasmid selection at 37 ◦C. Once an OD600nm of 0.5 was reached, cultures were
cooled down on ice, and protein expression was induced by addition of 0.5 mM IPTG. Following
incubation at 19 ◦C for 18 h, bacterial cells were harvested by centrifugation and resuspended in buffer
A (50 mM NaH2PO4, 500 mM NaCl, 5 mM imidazole, 0.1% Tween 20, pH 8; for depolymerases) or lysis
buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, 30% glycerol, pH 8; for LysK). Cells were
disrupted using a Stansted pressure cell homogenizer (SPCH-10-230V; Stansted Fluid Power, Harlow,
UK). Lysates were cleared by centrifugation, and target proteins purified from the crude extracts by
immobilized metal ion affinity chromatography using low-density nickel resin (ABT, Madrid, Spain)
in Econo-Pac gravity flow columns (Bio-Rad, Cressier, Switzerland). Proteins were eluted with buffer
B (50 mM NaH2PO4, 500 mM NaCl, 250 mM imidazole, 0.1% Tween 20, pH 8; for depolymerases) or
elution buffer (50 mM NaH2PO4, 300 mM NaCl, 250 mM imidazole, 30% glycerol, pH 8; for LysK).
Eluted fractions with high protein concentration were pooled, dialyzed against dialysis buffer (50 mM
NaH2PO4, 100 mM NaCl, 0.005% Tween 20, pH 8 for depolymerases; 50 mM NaH2PO4, 300 mM NaCl,
30% glycerol, pH 8 for LysK) and filter-sterilized (0.2 µM). Protein identity and purity were assessed
by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), protein concentrations
were measured spectrophotometrically (NanoDrop ND-100, NanoDrop Technologies, Wilmington, DE,
USA), and protein preparations were stored on ice.
2.4. Static Biofilm Model
Static biofilm reduction assays were conducted as previously described [21] to test the efficacy of
LysK, A. actinomycetemcomitans-derived polysaccharide depolymerases, and DNase I (Sigma-Aldrich,
Buchs, Switzerland) against S. aureus biofilms. In brief, biofilms were grown in TSB supplemented
with 0.25% D(+)-glucose (TSBG) in a polystyrene 96-well plate for 24 h at 30 ◦C. The biofilms were
washed with phosphate-buffered saline (PBS) and treated with serial dilutions of LysK for 2.5 h at
37 ◦C (standard protocol). In the case of the depolymerases and DNase I, the standard protocol was
modified and treatment was done for 30 min at 30 ◦C and for 1 h at 37 ◦C, respectively. For synergy
experiments with LysK and the depolymerase DA7, biofilms were treated for 1 h at 37 ◦C, representing
a compromise between the two conditions used for the individual enzyme treatments. After treatment,
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residual biofilms were washed with PBS, stained with 0.4% crystal violet (CV), and washed again.
The CV stain was dissolved in 96% ethanol, and the absorption at 595 nm (A595nm) of the resulting
solutions was measured spectrophotometrically.
2.5. Dynamic Biofilm Model
For studying the efficacy of LysK and DA7 to eradicate dynamically grown S. aureus biofilms,
a Biostream flow cell system [31,39] was employed. The flow cell consists of a molded silicone block
forming a flow chamber, which is sealed on the bottom side with a glass slide (Gerhard Menzel GmbH,
Braunschweig, Germany) serving as the surface for biofilm growth. Glass slides were pretreated
with a mix (2:1) of 98% sulfuric acid and 30% hydrogen peroxide to remove organic and inorganic
material and thoroughly washed with deionized water. The entire assembly, consisting of the flow cell,
silicon tubes (1.6 mm inner diameter) connected by straight and Y-shaped Kynar connectors (Fisher
Scientific, Reinach, Switzerland), and Schott Duran glass bottles equipped with two- and three-port
screw caps and pressure equalization sets (VWR, Dietikon, Switzerland) was autoclaved before use.
To ensure a continuous flow of medium during biofilm growth, the assembly was connected to a
Minipuls Evolution peristaltic pump (Gilson, Middleton, WI, USA). To initiate biofilm growth, 20 mL
of a S. aureus SA113 overnight culture were centrifuged (7000× g for 20 min), and the pellet was
resuspended in PBS to an OD600nm of 1. The flow cells were first filled with PBS, followed by the
S. aureus suspension for 20 min at a flow rate of 570 µL/min (resulting in shear forces of 10−2 Pa),
and then incubated for 20 h at 4 ◦C, 10 ◦C, 19 ◦C (chosen as the standard procedure after preliminary
experiments), 25 ◦C or 37 ◦C under constant flow (570 µL/min) of TSBG. Flow cells were then
disassembled, the glass slides containing the biofilms washed in PBS and subsequently submerged
in solutions of LysK and/or DA7 or buffer as a control for 2 or 5 h at 25 ◦C. Following treatment,
the slides were washed with PBS, and residual biofilm on the slides was quantified by CV staining as
described above for the static biofilm model. Alternatively, the number of residual viable S. aureus
cells on the slides was determined by vortexing the glass slides with 5 mL of Marienfeld Superior soda
lime glass beads (Fisher Scientific) in 30 mL PBS for 30 s and plating serial dilutions of the supernatant
on agar plates for enumeration of colonies.
2.6. Determination of Synergy between LysK and DA7
To determine synergistic effects between LysK and DA7 against S. aureus biofilms in a static model,
2-fold serial dilutions of both enzymes starting with their respective minimum biofilm eradication
concentrations (MBECs) as highest concentrations were prepared. The MBEC was defined as the
lowest concentration of an agent required to remove all visible biofilm from the polystyrene surface in
the static biofilm reduction assay as described above. The efficacies of these serially diluted individual
enzymes (MBECs x and y) at removing static S. aureus biofilms were then compared to those of 2-fold
serially diluted mixtures of both enzymes at different ratios ( 12 x +
1
2 y,
3
4 x +
1
4 y, and
1
4 x +
3
4 y).
For each mixture, the sum of fractional biofilm eradication concentrations (ΣFBEC; corresponding
to the sum of fractional inhibitory concentrations, ΣFIC, in a classical microdilution broth synergy
assay [40,41]) as a measure of synergy was calculated from the difference between the row containing
the first cleared well for the enzyme mixture and the row containing the first cleared wells for the
single enzymes [37]. In analogy to the classical synergy assays, enzyme combinations with a ΣFBEC
below 0.5 were considered synergistic [41]. To determine synergistic effects in the dynamic model,
the S. aureus biofilm was grown in 4 parallel flow cells as described above and treated with buffer
(control), DA7 (concentration x), LysK (concentration y), or a mixture of DA7 and LysK ( 14 x +
3
4 y)
for 2 h at room temperature. For each treatment, residual viable S. aureus cells were determined as
described above.
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2.7. Confocal Laser Scanning Microscopy
For confocal laser scanning microscopy (CLSM), S. aureus biofilms were grown essentially as
described above for the dynamic biofilm model with some modifications. Instead of Biostream flow
cells, 8-cell µ-Slide VI0.4 flow cells (IBIDI, Martinsried, Germany) were used. Due to the smaller
dimensions of these cells, the flow rate was reduced to 60 µL/min in an effort to achieve similar
shear forces (10−2 Pa) as in the Biostream setup. Biofilms were washed with PBS at the same flow
rate before filling the cells with enzyme solution and incubating them without flow for 2 h at 25 ◦C.
After treatment, the cells were washed again, and residual biofilms in the cells were stained with
live/dead stain (LIVE/DEAD BacLight; Life Technologies, Carlsbad, CA, USA) diluted 1:1 with PBS
for 15 min. After another wash with PBS, biofilms were visualized by CLSM, using a Leica TCS SPE
system (Leica Microsystems, Wetzlar, Germany). Three-dimensional reconstructions of biofilms were
generated in silico from recorded z-stacks using the software ImageJ [42].
2.8. Statistical Analysis
One-way analysis of variance (ANOVA) with a post hoc Tukey honestly significant difference
(HSD) test was used for multiple means comparisons or Welch’s t-test for two-mean comparisons in
dynamic biofilm reduction experiments.
3. Results
3.1. The Bacteriophage Endolysin LysK Is Active against Biofilms of Multiple S. aureus Strains
To determine the activity of LysK against biofilms of multiple S. aureus strains, a selection of
strains from our laboratory collection (Table 1) was first assessed for their ability to form biofilms on
polystyrene surfaces in a static 96-well plate-based model. These included SA113, a reportedly strong
biofilm former and producer of PNAG [32,43], which served as a positive control in this experiment;
three bovine mastitis isolates from different geographic regions; multiple food isolates; and RN6911,
a mutant strain deficient of the accessory gene regulator (agr) [33]. Expression of this regulator results
in enhanced biofilm dispersal [44] and, therefore, the mutant strain was expected to be a strong biofilm
producer. In fact, RN6911 demonstrated the best biofilm forming ability of all tested strains, as revealed
by CV staining of biofilms grown for 24 h at 30 ◦C (Figure 1A). In addition, SA113, the mastitis strain
SA001, and the food isolates R174 and R177 were found to produce strong biofilms. The remaining
strains were classified as moderate biofilm formers, with the exception of strain 350, which only
produced weak biofilms. We then tested the efficacy of LysK against biofilms of each of these strains in
the static model. To this end, the biofilms were exposed to two-fold serial dilutions of the endolysin for
2.5 h, and residual biofilms were stained with CV and quantified spectrophotometrically, as exemplified
for SA113 in Figure 1B. The susceptibility of each strain to LysK degradation was rated based on the
concentration-dependent reduction in biofilm mass (Figure 1A). The majority of strains were highly
susceptible to the action of the endolysin, with concentrations as low as 40 nM causing a reduction in
biofilm mass. Only strains Newbould and R174 showed a higher degree of recalcitrance to the enzyme,
with none of the tested enzyme concentrations reducing the biofilm by more than 40%.
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liquids. To better account for these factors, we tested the efficacy of LysK against S. aureus biofilms
grown under dynamic conditions, using a Biostream flow cell assembly. In a series of preliminary
experiments, biofilm growth of S. aureus SA113 within 20 h in this setup was evaluated at various
different temperatures ranging from 4 ◦C to 37 ◦C. While incubation at 4 ◦C resulted in no visible
biofilm growth under the applied conditions, incubation at 37 ◦C yielded large bacterial aggregates.
However, these often showed insufficient attachment to the glass surface, which resulted in frequent
clogging of the flow cell and an overall low reproducibility of the experiments [45]. The temperature
that yielded the best results in terms of reproducibility and, at the same time, represented a reasonable
compromise between biomass production and stable attachment to the surface was 19 ◦C. For these
reasons, this incubation temperature was chosen for all further dynamic biofilm experiments in this
study. When SA113 biofilms grown under these conditions were submerged in LysK solutions of
various concentrations (ranging from 0.31 to 1.25 µM) for 5 h, we observed a concentration-dependent
removal of the biofilms from the glass surfaces, as demonstrated by CV staining of residual biofilms
followed by spectrophotometric quantification of the solubilized stain (Figure 2A,C).
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Both 1.25 and 0.63 µM LysK caused a reduction in the A595nm by approximately 80% compared to
the control (biofilms submerged in buffer without enzyme). At an endolysin concentration of 0.31 µM,
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the biofilm-disrupting effect was markedly reduced (approximately 60% reduction compared to the
control). When the incubation time was shortened to 2 h, 1.25 µM LysK was still able to decrease
the A595nm by more than 70%, which was not significantly different (p > 0.05) from the 5 h treatment.
Therefore, the 2 h incubation was adopted as the standard procedure in the subsequent experiments.
3.3. A. actinomycetemcomitans-Derived PNAG Depolymerases Disrupt S. aureus Biofilms
In an effort to identify agents with the ability to disrupt the extracellular matrix of S. aureus
biofilms, putative PNAG depolymerases from five different A. actinomycetemcomitans strains (Table 1)
were cloned and produced in E. coli as N- and C-terminally 6×His-tagged recombinant proteins.
Cloning, expression, and purification by IMAC was successful for 7 out of 10 constructs, and nucleotide
sequencing revealed high similarity (>90%) of all proteins with the previously described PNAG
depolymerase dispersin B [27]. Cloning was not successful for the remaining three constructs.
All purified depolymerases were then compared for their ability to remove S. aureus biofilms
in the static model. While all C-terminally His-tagged enzymes exhibited approximately two-fold
higher activity than their N-terminally His-tagged counterparts, no significant differences in activity
within the group of N-terminally His-tagged proteins or within the group of C-terminally His-tagged
proteins were found [45]. Therefore, one of the C-terminally His-tagged depolymerases, DA7,
which was consistently produced at high yields and purity (Figure 3A), was selected for further
analysis. DA7 demonstrated high biofilm-disrupting activity, removing statically grown biofilms from
polystyrene surfaces at low nanomolar concentrations (MBEC 2.5 nM; Figure 3B,C). In addition, in the
dynamic model, DA7 eliminated all visible biofilm at concentrations as low as 6.25 nM (Figure S1).
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biofilms were grown at 30 ◦C for 24 h, treated with increasing concentrations of DA7 (top) or buffer as
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3.4. ase I Is ctive against S. aureus SA113 Biofilms at High Concentration
Besides exopolysaccharides and proteins, extracellular DNA has been reported to be an important
component f staphylococcal biofilms [46]. Aiming at a ulti-enzyme approach in which various
components of th extracellular matrix of S. aureus biofilms are targeted simultaneously, we evaluated
the effect of DNase I against SA113 biofilms grown in the static model. Similar to our observations
with DA7, DNAse I caused a concentration-dep dent removal of the bi films from the polystyrene
surfaces (Figure S2). Howev r, the DNAse I concentrations required to achieve effects similar to those
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of DA7 were relatively high, with an MBEC of 250 µg/mL (approximately 8 µM), compared to 2.5 nM
for DA7. For this reason, the inclusion of DNAse I in a combination treatment with LysK was not
further pursued.
3.5. LysK and DA7 Act Synergistically to Degrade S. aureus Biofilms in Both Static and Dynamic Models
The high efficacy of the depolymerase DA7 at removing S. aureus biofilms in both static and
dynamic models led us to investigate the effect of a combined treatment with LysK and DA7 in an
effort to achieve enhanced degradation of biofilm mass besides inactivation of staphylococcal cells. To
this end, the efficacies of the two individual enzymes against SA113 biofilms were compared with those
of enzyme mixtures at different ratios in the static biofilm model (Figure 4A). The mean ΣFBEC values
obtained for the combination treatment with DA7 and LysK at the ratios 50:50, 75:25, and 25:75 in these
experiments were 0.38 ± 0.14, 0.50 ± 0.00, and 0.31 ± 0.13, respectively, suggesting a synergistic effect
of the two enzymes against SA113 biofilms. Based on these results, we further explored whether this
synergistic effect can also be observed against biofilms grown under dynamic conditions. Therefore,
SA113 biofilms grown on glass slides in four parallel Biostream flow cells were exposed to either buffer
as a control, DA7, LysK, or a mixture of both enzymes at the ratio of 25:75, which had proven most
effective in the static model. Residual biofilms after treatment were recovered from the glass slides
and the concentrations of viable bacteria determined. All enzyme treatments significantly reduced
the number of viable cells on the glass slides compared to the control treatment, with the DA7/LysK
combination treatment being most effective (Figure 4B). The enzyme mixture caused a reduction in
CFU/mL by approximately 2.5 log units, which was significantly (p < 0.05) more than the reductions
caused by either individual enzyme treatment and is in agreement with the results from the static
synergy assays.
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both enzymes, and residual bacterial cells in the µ-slides after treatment were live/dead stained prior
to microscopy. Three-dimensional reconstructions of the biofilms after various treatments generated
from recorded z-stacks are shown in Figure 5. Compared to the control treatment (Figure 5A), exposure
to DA7 resulted in a reduced thickness of the biofilm adhering to the slide by approximately 50%.
However, the depolymerase had no visible effect on the viability of the residual cells (Figure 5B).
In contrast, LysK killed the majority of the bacteria, including those close to the bottom of the biofilm,
suggesting that the endolysin is able to deeply penetrate the biofilm and exert its bactericidal effect.
Despite this strong killing activity, many of the dead cells (and/or extracellular DNA released upon
cell lysis) appeared to remain bound within the residual biomass attached to the slides (Figure 5C).
When biofilms were exposed to a mixture of DA7 and LysK at the ratio 25:75, both the overall bacterial
density on the slide surface and the number of viable cells remaining after treatment were markedly
reduced compared to the control, underlining the synergistic effect of the depolymerase and the
endolysin against S. aureus biofilms.
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studies employed microtiter plate-based biofilm models or other static setups, and there is a general lack
of endolysin efficacy studies against dynamically grown biofilms using flow cell models. One exception
is a recent study by Becker et al., who reported that chimeric peptidoglycan hydrolases featuring three
unique enzymatic activities were able to reduce the concentration of viable cells in S. aureus biofilms
dynamically grown within a commercial microchannel flow cell by up to 0.89 log units within 2 h at a
concentration of 1.4 µM [50]. As opposed to such microchannel systems, the Biostream flow cell used
here has a volume of approximately 1 mL and allows removal of the biofilm contact surface without
the necessity to break parts of the assembly. This system ensures a linear flow profile over the entire
width of the chamber [31], simulating flow conditions as they are expected to occur in the bloodstream,
in food processing facilities, or in milk canals within the bovine udder. When S. aureus biofilms grown
under these conditions were treated with LysK at a concentration of 1.25 µM for 2 h, the number of
residual viable cells on the slides was reduced by approximately 1.7 logs (Figure 4B). CV staining of
LysK-treated biofilms revealed a noticeable difference in the way the biofilms were removed from
the glass slides between the 2 h and the 5 h treatments (Figure 2). Although the overall reduction in
biomass was similar for both treatment times, biofilms exposed to the endolysin for 2 h were sloughed
off the surface in large fragments when applying mechanical forces during the post-treatment washes.
In contrast, biofilms treated for 5 h showed a higher degree of stickiness, leaving thin layers of biomass
on the slides after the washing step. This could be explained by increased release of DNA from dead
bacterial cells that are exposed to the endolysin for extended periods of time. This is in agreement
with the DA7-mediated biofilm removal, where no such sticky residues were observed (Figure S1).
Due to its activity against the extracellular biofilm matrix but not the staphylococcal cells, no increase
in extracellular DNA is to be expected in this case.
Despite our efforts to apply similar shear forces to growing biofilms in the Biostream flow cell
and the IBIDI µ-slides used for CLSM, it cannot be ruled out that biofilms produced in the two systems
are different, particularly regarding their 3D structure. However, the finding that the results obtained
in the CLSM experiments for the different treatments are largely in agreement with those obtained
with the Biostream flow cell argues against a significant impact of the flow cell system used on the
susceptibility of the produced biofilms to the enzymes.
Given the high degree of similarity of DA7 and other A. actinomycetemcomitans-derived
depolymerases investigated in this work with the previously described dispersin B [27], it is safe
to assume that these proteins exhibit the same enzymatic specificity and mechanism of action in
hydrolyzing poly-β(1,6)-N-acetyl-D-glucosamine present in the extracellular biofilm matrix of many
staphylococcal strains [54]. This also explains why all depolymerases within the group of C-terminally
His-tagged proteins showed similar levels of efficacy against static biofilms, and the same was true for
all depolymerases within the group of N-terminally His-tagged proteins [45]. However, there was a
consistent difference in activity between the C-terminally His-tagged versions of the enzymes and their
N-terminally His-tagged counterparts [45]. The most likely reason for the reduced activity of the latter
versions is that a His-tag fused to the N-terminus of the enzyme interferes with the conformation of
the protein in an unfavorable manner or impedes access of the substrate to the catalytic center. This is
in line with the finding that the enzymatically active site of dispersin B is located in the N-terminal
portion of the enzyme [55].
When compared on a molar basis, the capacity of DA7 to remove S. aureus biomass from glass
and polystyrene surfaces surpasses that of LysK by several orders of magnitude in both static and
dynamic models. However, it should not be forgotten that DA7 is not bactericidal, whereas the
endolysin LysK effectively kills S. aureus even within deeper layers of the biofilm, as demonstrated
by CLSM of live/dead-stained biofilms (Figure 5). Furthermore, endolysins have been reported to
be active against persister cells, a capability of high relevance in the context of biofilms, which are
known to harbor a high proportion of slow- or non-growing bacteria [23]. This clearly argues for
a combined application of endolysins and depolymerases, as has been investigated for LysK and
DA7 in this work. The synergistic effect of these two enzymes used in combination against S. aureus
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biofilms was demonstrated in both static and dynamic models. It can most likely be attributed
to facilitated access for LysK to S. aureus cells embedded within the biofilm matrix when PNAG,
an important component of this matrix, is degraded by DA7. Likewise, disintegration of bacterial
cell walls by LysK may enable DA7 to penetrate into deeper layers of the biofilm, which overall leads
to a more effective destabilization of the three-dimensional structure. Besides the observed synergy,
the activities of the individual enzymes were found to be similar when comparing static and dynamic
models. In both cases, LysK and DA7 removed the majority of visible biofilm at low micromolar
and low nanomolar concentrations, respectively, suggesting that dynamically grown biofilms do not
show a substantially higher level of recalcitrance against the enzymes under the conditions applied
here. While different surface materials may affect the adhesion capacity of bacterial cells, it has been
suggested that polystyrene (as used in our static model) and glass (as used in the Biostream flow cell)
do not significantly differ in the attachment capacity of various organisms, including S. aureus [56].
However, it should be noted that direct comparison of results from the static and dynamic models is
difficult due to the different growth and treatment conditions applied in the two models.
Staining of biofilms with CV as it has been applied here in both static and dynamic models is one
of the most widely used methods for quantification of adhered biomass. It offers several advantages
such as versatility and high throughput capability. Furthermore, it avoids the necessity to detach
biofilms from their growth surfaces, as required for enumeration of viable cells. At the same time,
one needs to be aware of the drawbacks of this method. These include a lack of reproducibility and
sensitivity and a possible over- or underestimation of biofilm mass in dependence of the washing steps
(reviewed in [57]).
S. aureus strain SA113, which was used in most static and dynamic biofilm experiments in this
study, is a reportedly strong biofilm former that is known to produce PNAG as a major component of
its extracellular matrix [43]. This explains the high efficacy of the PNAG-depolymerase DA7 against
SA113 biofilms, as shown here. At the same time, it implies that DA7 is inactive against biofilms of
S. aureus strains incapable of PNAG production or for which PNAG is not a major extracellular matrix
component, as has been demonstrated for the DA7-homologue dispersin B [58]. It is important to note
that the icaADBC locus, which is responsible for PNAG production, is present in the majority of all
S. aureus clinical isolates [59], and that production of PNAG has been shown to be a crucial factor for
S. aureus pathogenesis in murine models of systemic infection [60] and in S. aureus-induced bovine
mastitis [14]. One non-dispersin B-like exopolysaccharide depolymerase named Dpo7 with activity
against S. aureus biofilms has recently been described [29]. However, the exact molecular target of this
phage-derived enzyme is still unknown.
Aiming at a multi-enzyme approach to eradicate S. aureus biofilms, we also investigated the ability
of DNase I to reduce SA113 biofilms by degrading extracellular DNA. Our results are in agreement
with previous studies, which had found that DNase I compromised the integrity of biofilms formed by
various S. aureus strains, leading to their detachment [26,58,61]. However, under the conditions applied
in our work, the DNase I concentrations required to achieve similar effects as for DA7 were more than
1000-fold higher when compared on a molar basis. Therefore, DNase I was not included in the synergy
experiments in this study. However, similar to what has been discussed for DA7, susceptibility to
DNase I can vary from strain to strain, likely depending on the proportion of extracellular DNA within
the biofilm matrix.
Strain-dependent differences in efficacy against S. aureus biofilms were also observed for LysK,
even though the endolysin displayed strong activity against the majority of the strains tested here
in the static model. This is consistent with a previous report, in which the staphylococcal phage
endolysin LysGH15 was shown to degrade biofilms of more than 30 staphylococcal strains from
different species (S. aureus, S. epidermidis, S. hominis, and S. haemolyticus) grown for 24 or 72 h in a
static model [47]. LysGH15 is almost identical with LysK, differing from the latter in only four amino
acids [19]. Furthermore, LysK has demonstrated strong lytic activity against planktonic cells of a
large set of staphylococcal strains, including clinical S. aureus isolates (MSSA and MRSA), bovine
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mastitis isolates, coagulase-negative staphylococci, and multiple mutant strains with altered surface
structures [21]. Taken together, these results provide further evidence that LysK is a potent staphylolytic
enzyme with a broad spectrum of activity against planktonic cells and biofilms. However, further
studies are required to investigate whether this holds true when LysK is used against dynamically
grown biofilms of multiple strains, alone or in combination with DA7.
It is important to understand that the growth conditions (and growth temperatures in particular)
applied in the biofilm experiments in this work were not chosen in order to optimally simulate
conditions found in either clinical/veterinarian or food safety environments or to allow direct
comparison between the static and dynamic models, but in an effort to produce the most stable and
reproducible biofilms within each given setup. When aiming at specific applications in either of these
settings, further experiments beyond the scope of the current study are advisable. These could include
investigating the impact of various parameters such as media composition, growth temperature,
incubation time, surface material and surface coatings on the growth of S. aureus biofilms and their
susceptibility to LysK and DA7. Further, it could be relevant to investigate mixed-species biofilms and
their susceptibility to these combined treatment strategies, since they are prevalent in most settings
outside the laboratory [62,63]. Moreover, it could be interesting, at least from a scientific perspective,
to assess the potential of both enzymes to prevent biofilm growth as opposed to disruption of mature
biofilms. While preventive application may not be viable in food production due to the high costs
associated with it, it may be feasible in certain niche medical applications, e.g., following surgery for
insertion of prosthetic joints or catheters.
In the context of medical and veterinarian applications, a combination of our enzyme-based
approach with classical antibiotic treatment, as has been suggested previously [64], could constitute
an effective therapy against S. aureus infections involving biofilms. In bovine mastitis treatment,
biofilm-degrading enzymes could contribute to the declogging of milk ducts congested by aggregates
of bacterial and somatic cells in order to facilitate penetration of the udder by antibacterial agents
administered intramammarily. Finally, biofilm-disrupting enzymes could be part of an effective hurdle
technology applied in food production and processing facilities to alleviate the risk of biofilm-mediated
contamination of food products.
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static conditions.
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